Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/20/25
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's DiseaseGlobeNewsWire • 11/13/25
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical ProgramsGlobeNewsWire • 11/06/25
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 10/08/25
These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025The Motley Fool • 09/03/25
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment TargetGlobeNewsWire • 09/03/25
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)GlobeNewsWire • 09/02/25
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common StockGlobeNewsWire • 08/28/25
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 08/26/25
Cognition: Zervimesine AD Treatment Program FDA Alignment Means "Strong Buy" RatingSeeking Alpha • 08/26/25
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's DiseaseGlobeNewsWire • 08/12/25
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's DiseaseGlobeNewsWire • 07/29/25
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's DiseaseGlobeNewsWire • 07/21/25
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAICGlobeNewsWire • 07/16/25
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's DiseaseGlobeNewsWire • 07/10/25
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment TargetGlobeNewsWire • 07/01/25
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)GlobeNewsWire • 06/25/25
Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy BodiesGlobeNewsWire • 06/03/25
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy BodiesGlobeNewsWire • 05/28/25
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell HealthGlobeNewsWire • 05/09/25
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business UpdateGlobeNewsWire • 05/07/25
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease ProcessesGlobeNewsWire • 04/01/25
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025GlobeNewsWire • 03/25/25